🧪 The performance qualification process will occur at Recipharm’s facility in Germany. Both companies aim for an efficient path to manufacturing, enhancing supply chain capabilities as they prepare for commercial readiness.
🌍 This marks a significant advance in live biotherapeutics globally!
Introduction:
This article discusses the collaborative efforts between Recipharm Advanced Bio and Infant Bacterial Therapeutics (IBT) aimed at the commercial drug production of IBT’s lead product, IBP-9414. The partnership emphasizes the process performance qualification (PPQ) of this innovative product, which is expected to be the first live biotherapeutic product (LBP) available globally.
- Recipharm Advanced Bio and IBT are initiating a PPQ program for IBP-9414 at Recipharm’s microbial manufacturing facility in Cuxhaven, Germany.
- The collaboration leverages IBT’s innovative strategies alongside Recipharm’s expertise in microbial manufacturing to ensure efficient project timelines.
- IBP-9414 is significant as it will be the first LBP globally, indicating a breakthrough in biotherapeutics.
- Recipharm’s Cuxhaven facility supports a comprehensive range of services, from preclinical development to commercial production, ensuring integrated solutions for bacterial capabilities.
- The partnership also aims to solidify Recipharm’s potential role as a future drug substance supplier for IBT, enhancing their commercial supply chain dynamics.
Conclusion:
The collaboration between Recipharm Advanced Bio and Infant Bacterial Therapeutics is set to advance the development and commercial readiness of IBP-9414, which may redefine the landscape of live biotherapeutics. This partnership not only highlights the innovative approaches in drug development but also strengthens the operational capabilities of both organizations, paving the way for future advancements in biotech manufacturing and supply chain efficiency.
